Dextroamphetamine (Dexedrine, Zenzedi) for adults

Dextroamphetamine is the "dextro" form of amphetamine and one of the oldest ADHD medications. It is sold as immediate-release tablets (brand Zenzedi and generics), a sustained-release capsule (Dexedrine Spansule and generics) and an oral solution (ProCentra and generics). It is also the active medication that Vyvanse turns into in the body. This page explains what the current FDA labels say, and one point surprises many adults: the oral dextroamphetamine labels describe ADHD use only in children and teenagers.

What it is

The labels describe dextroamphetamine sulfate as "the dextro isomer of the compound d,l-amphetamine sulfate, a sympathomimetic amine of the amphetamine group." It is a CNS stimulant, and federal law lists amphetamine, including its optical isomers, in Schedule II. Mixed amphetamine salts products such as Adderall contain both the dextro and levo forms; dextroamphetamine products contain only the dextro form.

Forms and how long they last

The Spansule label explains that each capsule "is so prepared that an initial dose is released promptly and the remaining medication is released gradually over a prolonged period." The tablets and solution are immediate-release, and the labels advise avoiding late evening doses because of insomnia. The patch is covered separately in amphetamine liquids, dissolving tablets and the patch.

Is it approved for adults?

For oral dextroamphetamine, not for ADHD. Each label has two indications:

• Narcolepsy, with no upper age limit (the narcolepsy dosing directions include patients 12 and older).
• ADHD, worded for young people: the Dexedrine label says "patients (ages 6 years to 16 years)," and the Zenzedi, generic tablet and oral solution labels say "pediatric patients (ages 3 to 16 years)."

So when a prescriber uses oral dextroamphetamine for ADHD in an adult, that is outside the label's age wording, which is called off-label use. It is reasonable to ask why a product is being chosen and what evidence supports it for you. The labels also contain no adult ADHD trial data.

The exception is the Xelstrym patch, whose label indicates it for ADHD "in adults and pediatric patients 6 years and older." Lisdexamfetamine (Vyvanse), which the body converts to dextroamphetamine, is also approved for adults.

What guidelines say

The UK's NICE guideline (NG87) recommends lisdexamfetamine or methylphenidate as first-line medication for adults. It says to consider dexamfetamine (the UK spelling) "for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile," and notes that this is off-label there too. A 2018 network meta-analysis in Lancet Psychiatry, which grouped amphetamine products together, found amphetamines reduced adult ADHD symptoms more than placebo in short-term trials. For the wider evidence, see does ADHD treatment work in adults.

The boxed warning

All the dextroamphetamine labels reviewed for this page carry the CNS stimulant boxed warning on abuse, misuse and addiction that the FDA required on May 11, 2023. The Dexedrine label says it "has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction," and that misuse can result in overdose and death, especially with higher doses or snorting or injection. See misuse and addiction risk.

Side effects listed on the labels

The oral labels list adverse reactions by body system rather than adult percentages:

• Heart: palpitations, fast heart rate, raised blood pressure; isolated reports of cardiomyopathy with chronic use.
• Nervous system: restlessness, overstimulation, dizziness, insomnia, tremor, headache, euphoria or low mood, worsening tics; rare psychotic episodes at recommended doses.
• Digestive: dry mouth, unpleasant taste, diarrhea, constipation, loss of appetite and weight loss.
• Other: hives, changes in libido or impotence, hair loss (on the Dexedrine label) and, rarely, rhabdomyolysis (muscle breakdown).

The warnings sections add the class risks: serious heart disease, blood pressure and heart rate increases, mania and psychosis, seizures, Raynaud's phenomenon and serotonin syndrome. See heart health and blood pressure and side effects in adults.

Who should not take it

The current labels list two contraindications: known hypersensitivity to amphetamine products, and use during or within 14 days of an MAOI because of the risk of hypertensive crisis. The Dexedrine label specifically includes linezolid and intravenous methylene blue among the MAOIs.

Interactions to mention

The labels name serotonergic drugs (SSRIs, SNRIs, triptans, tricyclics, lithium, tramadol, St. John's Wort and others) and CYP2D6 inhibitors because of serotonin syndrome risk; agents that alkalinize or acidify the stomach or urine, which raise or lower amphetamine levels; and blood pressure medicines, whose effect amphetamines may blunt. The Dexedrine label adds proton pump inhibitors such as omeprazole. See ADHD medication drug interactions.

Pregnancy and breastfeeding

These older labels say there are no adequate and well-controlled studies in pregnant women and describe animal findings and one case report of birth defects; infants of mothers dependent on amphetamines have a higher risk of premature delivery and low birth weight. On nursing, they say amphetamines are excreted in human milk and advise mothers to refrain from nursing. NIH LactMed adds that some evidence suggests prescribed doses might not affect nursing infants and that some experts allow use with infant monitoring. Plan this with your prescriber; see ADHD in pregnancy and postpartum.

Generics, cost and supply

Generic dextroamphetamine tablets, extended-release capsules and oral solution are listed on DailyMed from several manufacturers. Prices depend on your plan and pharmacy, so ask them. As of October 19, 2026, the FDA drug shortage database did not list dextroamphetamine products as a current shortage. See ADHD medication cost in New York.

New York and New Jersey rules

As a Schedule II drug, dextroamphetamine cannot be refilled under federal rules, though a prescriber may issue multiple dated prescriptions covering up to 90 days.

• New York: an I-STOP registry check before prescribing, plus state supply and timing rules: New York's stimulant rules.
• New Jersey: P.L.2026, c.40 (effective July 8, 2026) requires adults located in New Jersey who start a Schedule II stimulant by telehealth to have an in-person visit within 30 days, a contact every three months, and an in-person visit at least yearly. State rules also require a history, an exam, an NJPMP check and a treatment plan first: New Jersey's rules.
• Federal telehealth: DEA telemedicine flexibilities run through December 31, 2026, as of October 2026.

Dr. Shershow, a psychiatrist licensed in New York and New Jersey, provides medication management for adults when medication is appropriate. The office can explain how visits are arranged for patients located in New Jersey.

Questions to ask your prescriber

• Why dextroamphetamine rather than a product labeled for adult ADHD?
• Should I use the short-acting tablet, the Spansule, or both?
• How will we watch blood pressure, sleep and mood?
• Would the patch or lisdexamfetamine be an option if swallowing pills or timing is a problem?

See questions to ask before starting ADHD medication. Never start, stop or change a medication without your prescriber.